Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177831 | 0.84 | KDM1A (0.35) | TRPV1PBRM1HTR2BALDH1A1 | |
| SCHEMBL9141913 | 0.82 | TLR3 (0.43) | TRPV1OPRM1OPRK1HTR2BAKR1B1 | |
| SCHEMBL8515250 | 0.75 | OPRM1 (0.34) | OPRM1OPRK1HTR2BAKR1B1 | |
| SCHEMBL619444 | 0.74 | HDAC3 (0.39) | — | |
| SCHEMBL4420243 | 0.74 | HDAC3 (0.39) | TRPV1 | |
| SCHEMBL13499163 | 0.74 | HDAC3 (0.39) | TRPV1 | |
| SCHEMBL8537172 | 0.72 | IDO1 (0.36) | TRPV1OPRM1OPRK1HTR2BAKR1B1 | |
| SCHEMBL11000607 | 0.70 | KCNE1 (0.37) | PGRALDH1A1POLBTSHR | |
| SCHEMBL31085042 | 0.70 | TRPV1 (0.43) | TRPV1OPRM1OPRK1AKR1B1ALDH1A1 | |
| SCHEMBL19889295 | 0.69 | AHR (0.35) | PBRM1HTR2BAKR1B1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1971598-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007061670-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | TRPV1 3350/4885OPRM1 3933/4885OPRK1 2595/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | TRPV1 3350/4885OPRM1 3933/4885OPRK1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.